HR+/HER2- advanced breast cancer: How do the latest data on CDK4/6 inhibitors inform clinical decision-making?

touchEXPERT OPINIONS for touchONCOLOGY

Listen to leading experts in breast cancer share their opinion on the latest data which may help guide the use of CDK4/6 inhibitors in HR+/HER2- advanced breast cancer.

The experts

• Dr Luca Malorni - Hospital of Prato, Italy
• Prof. Aleix Prat - Hospital Clínic Barcelona, Spain
• Dr Barbara Pistilli - Gustave Roussy, Villejuif, France

This touchPODCAST is for HCPs only.

This activity is funded by an unrestricted independent medical education grant from Novartis and is provided by touchIME. 

For further information visit our website: https://touchoncology.com/education/cdk-inhibitors-breast-cancer/